Analysts expect BioCardia, Inc. (NASDAQ:BCDA – Get Rating) to announce earnings per share of ($0.23) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for BioCardia’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.40). BioCardia posted earnings of ($0.20) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 15%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that BioCardia will report full year earnings of ($0.72) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.44). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.70) to ($0.44). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow BioCardia.
BioCardia (NASDAQ:BCDA – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. BioCardia had a negative return on equity of 110.86% and a negative net margin of 1,261.32%. During the same quarter in the previous year, the firm earned ($0.16) EPS.
Shares of NASDAQ:BCDA traded up $0.03 during trading on Thursday, hitting $1.41. 400 shares of the company were exchanged, compared to its average volume of 170,765. The stock has a market cap of $24.60 million, a price-to-earnings ratio of -1.82 and a beta of 1.40. BioCardia has a fifty-two week low of $1.10 and a fifty-two week high of $5.10. The firm has a fifty day moving average price of $1.81 and a two-hundred day moving average price of $1.99.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCDA. Commonwealth Equity Services LLC bought a new stake in BioCardia in the 3rd quarter valued at $51,000. Millennium Management LLC bought a new stake in BioCardia in the 3rd quarter valued at $31,000. Virtu Financial LLC bought a new stake in BioCardia in the 4th quarter valued at $109,000. Dimensional Fund Advisors LP bought a new stake in BioCardia in the 1st quarter valued at $57,000. Finally, Vanguard Group Inc. boosted its stake in BioCardia by 57.9% in the 1st quarter. Vanguard Group Inc. now owns 650,523 shares of the company’s stock valued at $1,346,000 after purchasing an additional 238,554 shares during the period. Institutional investors and hedge funds own 15.40% of the company’s stock.
About BioCardia (Get Rating)
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
- Get a free copy of the StockNews.com research report on BioCardia (BCDA)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.